Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
- Author:
Ajit SOOD
1
;
Vineet AHUJA
;
Vandana MIDHA
;
Saroj Kant SINHA
;
C. Ganesh PAI
;
Saurabh KEDIA
;
Varun MEHTA
;
Sawan BOPANNA
;
Philip ABRAHAM
;
Rupa BANERJEE
;
Shobna BHATIA
;
Karmabir CHAKRAVARTTY
;
Sunil DADHICH
;
Devendra DESAI
;
Manisha DWIVEDI
;
Bhabhadev GOSWAMI
;
Kirandeep KAUR
;
Rajeev KHOSLA
;
Ajay KUMAR
;
Ramit MAHAJAN
;
S. P. MISRA
;
Kiran PEDDI
;
Shivaram Prasad SINGH
;
Arshdeep SINGH
Author Information
- Publication Type:Review
- From:Intestinal Research 2020;18(4):355-378
- CountryRepublic of Korea
- Language:English
- Abstract: Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.
